Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F14 in Patients Undergoing Unilateral Total Knee Replacement
NCT04860635Phase 3Suspended
- Sponsor
- Arthritis Innovation Corporation
- Start
- Jan 2027
- Primary completion
- Jul 2028
- Modality
- Injectable Hydrogels, Device-based Delivery, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of celecoxib in postoperative pain, sponsored by Arthritis Innovation Corporation. Planned start Jan 2027; status: suspended.
02
Drugs
celecoxib
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04860635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04860635.